Member Info for VertizeaSun

For pity's sake.....it's like persistent toothache.

RorkesDrift....there is a bigger market....for seniors and children as both groups are severely restricted to Dox'.....mainly because of damage to the heart..

AstraZeneca snubs Britain over £320m drug factory amid ‘discouraging’ taxes
Pharma giant to open plant overseas (Ireland) as bosses voice frustration over NHS levies

https://www.telegraph.co.uk/business/2023/02/09/britain-snubbed-320m-astrazeneca-drug-factory-discouraging-taxes/

Only two or three of the most senior people in a hospital would know the name of a test product.

Isn't there an American Avacta (no relation)?

Riesgo....the over funding was on a very small percentage of the money raised. The lion's share came from the US (Susquehanna) and not a lot from The City.

AS shouting loud and clear he's moving AVCT to Nasdaq - an institution capitalised at 90 times London AIM.

"Or it could possibly be the regulatory authority, the MHRA, even the FDA "

I do hope it's both. Interesting to see how long it takes them.....respectively. My skin begins to crawl when I hear a Brit civil servant is involved.

Possibly price. I think AS drives a hard bargain. Too hard?

give us a clue

NASDAQ is a natural home for AVCT ...... AIM's liquidity pool is far too low and the London X's can't properly value a company anyway. It's unfortunate for Alastair Smith but AIM shareholders will accept an offer around £7/8 per share or £2B.....so if AS wants to create another Roche he better get his skates on. Last summer MyMc thought a BO of AVCT likely by November/December,....wrong but leaving AS even less time to act.

https://twitter.com/MylesMcNulty/status/1615389589396672514

Myles McNulty

@MylesMcNulty
·
17m
Right now, at 155p, #AVCT is the cheapest it's ever been.

I am expecting things to move very quickly from here. Big Pharma will be all over
@avacta
right now.

An exceedingly happy shareholder who sees an enormous ROI from here in 2023.

Myles McNulty

@MylesMcNulty
·
Jan 12
Replying to @boy_cellar and @glr_1990
#AVA6000 data was ready pre-Xmas.

I know for a fact that #AVCT wouldn't announce a date for the Science Day, until they had all data in hand.

And were the data in hand, poor data, would they even want to hold a Science Day?

There are very big goings on right now at @avacta.

Bella...all possible but another view from Myles McNulty:

@MylesMcNulty
·
21h
Replying to @boy_cellar and @glr_1990
#AVA6000 data was ready pre-Xmas.
I know for a fact that #AVCT wouldn't announce a date for the Science Day, until they had all data in hand.
And were the data in hand, poor data, would they even want to hold a Science Day?
There are very big goings on right now at @avacta.

"tolerated and is activating" is a really good start and £3 even better. Mountains and molehills.

I wonder how the patients are doing?

Earlier on your Twitter feed....so AS might make a passing comment.

Phase 1a Dose Escalation Study

Secondary Objectives:

To evaluate the initial anti-tumour activity of AVA6000
according to RECIST.1.1 criteria (overall response rate
[ORR1. duration of response [DoR1, disease control rate
[DC] progression free survival [PFS ] and overall survival)

Morning all

Myles mixing it with the trolls:

"If my No.1 troll is to be believed (Eggysoldier / Bishop / Episcopus / Sacerdos on Twitter; NDN / Mr Adventurous on LSE), those at SP really don't like me."

https://twitter.com/MylesMcNulty/status/1612760905011314689